Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder.
Recently, aberrant coexpression of CD2 and CD25 has been reported to reliably distinguish neoplastic mast cells from normal or so-called reactive mast cells. Such expression is included in the consensus diagnostic criteria for systemic mast cell disease (SMCD). In our study of patients with SMCD, we found CD2 expression to be more prevalent on mast cells from patients without an associated haematological disorder (P = 0.04). Furthermore, no correlation was found between mast cell CD2 expression and other clinicopathological features in these patients.
Pardanani
Animesh
A
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Kimlinger
Teresa K
TK
Reeder
Terra L
TL
Li
Chin-Yang
CY
Tefferi
Ayalew
A
D000951:Antigens, Neoplasm / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000378:metabolism; D018801:CD2 Antigens / Q000378:metabolism*; D006402:Hematologic Diseases / Q000378:metabolism*; D006801:Humans; D008407:Mast Cells / Q000378:metabolism*; D034721:Mastocytosis, Systemic / Q000378:metabolism*; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000378:metabolism
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018801:CD2 Antigens; D015375:Receptors, Interleukin-2